Rahim N. Bispecific CAR-T vs. BCMA-Specific CAR-T: Advancing Treatment for Relapsed/Refractory Multiple Myeloma. HSET [Internet]. 2025 Sep. 5 [cited 2026 Sep. 7];153:42-7. Available from: https://hsetdata.com/index.php/ojs/article/view/1041